enGene Therapeutics (ENGN) Assets Average (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Assets Average of $322.3 million for Q2 2026, up 16.66% year-over-year from $276.3 million in Q2 2025, and up 15.41% quarter-over-quarter from $279.3 million in Q1 2026.
enGene Therapeutics (ENGN) Assets Average (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Assets Average for 3 consecutive years, with $322.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average rose 16.66% year-over-year to $322.3 million; the TTM figure through Apr 2026 stood at $322.3 million (up 16.66% YoY), while the FY2025 annual figure was $266.3 million, up 33.79% from the prior year.
- Assets Average climbed to $322.3 million in Q2 2026 per ENGN's latest filing, from $279.3 million in the prior quarter.
- Across five years, Assets Average topped out at $322.3 million in Q2 2026 and bottomed at $90.2 million in Q1 2024.
- Historically, Assets Average has averaged $249.9 million across 3 years, with a median of $273.2 million in 2024.
- On a YoY basis, Assets Average climbed as much as 231.03% in 2025 and fell as far as 19.21% in 2025.
- enGene Therapeutics' Assets Average stood at $289.0 million in 2024, then slipped by 19.21% to $233.5 million in 2025, then soared by 38.03% to $322.3 million in 2026.
- Business Quant data shows ENGN's Assets Average at $322.3 million in Q2 2026, $279.3 million in Q1 2026, and $233.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 19.82 Bn |
| 10 | enGene Therapeutics | 125.50 Mn | 125.50 Mn | - | 322.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 322.32 Mn |
| Jan 31, 2026 | 279.29 Mn |
| Oct 31, 2025 | 233.51 Mn |
| Jul 31, 2025 | 256.10 Mn |
| Apr 30, 2025 | 276.29 Mn |
| Jan 31, 2025 | 298.55 Mn |
| Oct 31, 2024 | 289.03 Mn |
| Jul 31, 2024 | 270.20 Mn |
| Apr 30, 2024 | 183.47 Mn |
| Jan 31, 2024 | 90.19 Mn |